Bibliography
- GOLD E, NANKERVIS GA: Viral infections of humans: Epidemiology and control. Evans AS, JR. (Ed.), Plenum Publishing Corp., New York, USA (1982).
- GOLDMAN RC, KLEIN LL: Problems and progress in opportunistic infections. Ann. Rep. Med. Chem. (1994) 29:155–164.
- WINSTON DJ, HO WG, CHAMPLIN RE: Cytomegalovirus infection after allogenic bone marrow transplantation. Rev. Infect. Dis. (1990) 12:5776–5792.
- GLENN J: Cytomegalovirus infection following renal transplantation. Rev. Infect. Dis. (1981) 3:1151–1178.
- FAULDS D, HEEL RC: Ganciclovir. A review of itsantiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs (1990) 39:597–638.
- CHRISP P, CLISSOLD SP: Foscarnet. A review of itsantiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs (1991) 41:104–129.
- DE CLERCQ E: Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Vim]. (1993) 3:85–96.
- DE CLERCQ E: Fomivirsen. Drugs (1999) 57:381–386.
- XIONG X, SMITH JL, CHEN MS: Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. (1997) 41:594–599.
- MCCARTHY M: Oral ganciclovir fails to prevent CMV in HIV trial. Lancet (1995) 346:895–899.
- BOIVIN G, CHOU S, QUIRK MR, ERICE A, JORDAN MC:Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leucocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. (1996) 173:523–528.
- WELCH AR, WOODS AS, MCNALLY LM, COTTER RJ, GIBSON WA: A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl. Acad. Sci. USA (1991) 188:10792–10796.
- FLYNN DL, ABOOD NA, HOLWERDA BC: Recent advances in antiviral research: identification of inhibitors of the herpesvirus proteases. Curr. Opin. Chem. Biol. (1997) 1:190–196.
- •A report on the identification of small size molecules inhibitors of herpes virus proteases.
- TONG L, QIAN C, MASSARIOL MJ, BONNEAU PR, CORDINGLEY MG, LAGACE L: A new serine-protease folds revealed by the crystal structure of human cytomegalovirus protease. Nature (1996) 383:272–275.
- TONG L, QIAN C, MASSARIOL MJ, DEZIEL R, YOAKIM C,LAGACE L: Conserved mode of peptidomimetic inhibition and substrate regulation of HCMV protease. Natural Struct. Biol. (1998) 5:819–826.
- POST LE: Gene therapy: progress, new directions andissues. Ann. Rep. Med. Chem. (1995) 30:219–226.
- HOLWERDA BC: Herpesvirus proteases: targets fornovel antiviral drugs. Antiviral Res. (1997) 35:1–21.
- •A review on structure and functionality of herpesvirus proteases.
- FLYNN DL, BECKER, DP, DILWORTH VM et al.: The herpesvirus protease: mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease. Drug Design Discover)/ (1997) 15:3–15.
- •A report on herpesvirus protease focused on HCMV protease and its first inhibitors.
- NASSIRI MR, EMERSON SG, DEVIVAR RV, TOWNSEND LB,DRACH JC, TAICHMAN RS: Comparison of benzimida-zole nucleosides and ganciclovir on the in vitro prolif-eration and colony formation of human marrow progenitor cells. Br. J. Haematol. (1996) 93:273–279.
- BROWN F, BANKEN L, SAYWELL K et al.: Pharmacoki-netics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin. Pharmacoki (1999) 37:167–176.
- PESCOVITZ MD, RABKIN J, MERION R et al.: Valganci-clovir provides ganciclovir plasma exposures similar to IV ganciclovir in transplant recipients. Transplantation (1999) 67:480
- ZACNY VL, GERSHBURG E, DAVIS MG etal.: Inhibition ofEpstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5,6-dichloro2-(isopropylamino)-1-b-L-ribofuranosyl-111-benzimidazole. j Vim]. (1999) 73:7271–7277.
- MARTINEZ A, ESTEBAN Al, CASTRO A et al.: Novelpotential agents for human cytomegalovirus infection: synthesis and antiviral evaluation of benzothiadiazine dioxide acyclonucleosides. J. Med. Chem. (1999) 42:1145–1150.
- MARTINEZ A, GIL C, CASTRO A et al.: Chlorophenyl-methyl benzothiadiazine dioxides derivatives: potent human cytomegalovirus inhibitors. Bioorg. Med. Chem. Lett. (1999) 9:3133–3136.